Testing Tumor-Treating Field therapy for EGFR lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This pilot study tests a device-based therapy (“Tumor Treating Fields,” TTFields) in people with non-small cell lung cancer (NSCLC) who have an EGFR mutation. The study aims to understand how this treatment affects outcomes and whether it can be done safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have confirmed lung cancer based on tumor or cell testing
- Have tumor testing showing an EGFR mutation (from a CLIA-approved lab test)
- Have at least one measurable tumor area that can be tracked on scans
- Be able to attend study visits and follow study instructions
- Not have a pacemaker or other implanted electronic device in the upper chest/torso
- Not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a device that sends low-energy electrical fields (called Tumor Treating Fields) to the lung tumor before surgery. The goal is to see if it can help shrink the tumor and improve surgical outcomes.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This study uses leftover tissue samples from people with EGFR-mutant non-small cell lung cancer to test how well different drugs work against their tumor cells. It may help guide future treatment decisions.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.